DOP2016000283A - Anticuerpos anti-rnf43 novedosos y métodos para su uso - Google Patents
Anticuerpos anti-rnf43 novedosos y métodos para su usoInfo
- Publication number
- DOP2016000283A DOP2016000283A DO2016000283A DO2016000283A DOP2016000283A DO P2016000283 A DOP2016000283 A DO P2016000283A DO 2016000283 A DO2016000283 A DO 2016000283A DO 2016000283 A DO2016000283 A DO 2016000283A DO P2016000283 A DOP2016000283 A DO P2016000283A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methods
- rnf43
- novels
- new
- drug conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención divulga anticuerpos anti-RNF43 novedosos y derivados de los mismos, incluyendo a conjugados de anticuerpo y fármaco, y métodos para usar dichos anticuerpos anti-RNF43 y conjugados de anticuerpo y fármaco para diagnosticar y tratar cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461982294P | 2014-04-21 | 2014-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2016000283A true DOP2016000283A (es) | 2016-11-30 |
Family
ID=54333409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2016000283A DOP2016000283A (es) | 2014-04-21 | 2016-10-19 | Anticuerpos anti-rnf43 novedosos y métodos para su uso |
Country Status (18)
Country | Link |
---|---|
US (1) | US20170073430A1 (es) |
EP (1) | EP3134121A4 (es) |
JP (1) | JP2017518040A (es) |
KR (1) | KR20170010764A (es) |
CN (1) | CN106714831A (es) |
AU (1) | AU2015249887A1 (es) |
BR (1) | BR112016024525A2 (es) |
CA (1) | CA2946308A1 (es) |
CL (2) | CL2016002667A1 (es) |
CR (1) | CR20160486A (es) |
DO (1) | DOP2016000283A (es) |
EA (1) | EA201692100A8 (es) |
IL (1) | IL248399A0 (es) |
MA (1) | MA39896A (es) |
MX (1) | MX2016013857A (es) |
PH (1) | PH12016502061A1 (es) |
SG (1) | SG11201608715WA (es) |
WO (1) | WO2015164392A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2647707T (pt) | 2010-11-30 | 2018-11-15 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de toxicidade |
TW201800420A (zh) * | 2016-05-20 | 2018-01-01 | 艾伯維史坦森特瑞斯有限責任公司 | 抗ascl1抗體及使用方法 |
JP2020514303A (ja) * | 2017-01-11 | 2020-05-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | R−スポンジン(rspo)サロゲート分子 |
EP3574019A4 (en) | 2017-01-26 | 2021-03-03 | Surrozen, Inc. | TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF |
WO2018203567A1 (en) * | 2017-05-02 | 2018-11-08 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2019143961A2 (en) * | 2018-01-19 | 2019-07-25 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors |
CN112654363A (zh) * | 2018-07-09 | 2021-04-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
CN113508127A (zh) * | 2018-11-06 | 2021-10-15 | 阿尔萨泰克公司 | 神经变性疾病的基于细胞的基因疗法 |
CA3141632A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors |
WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
CN112480250B (zh) * | 2020-12-23 | 2022-03-15 | 上海交通大学 | 一种抗人骨桥蛋白的抗体及其应用 |
EP4288458A1 (en) * | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
CA3211478A1 (en) | 2021-03-16 | 2022-09-22 | Naoya Tsurushita | Bifunctional molecules for treatment of immune disorders |
CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
WO2024025878A2 (en) * | 2022-07-25 | 2024-02-01 | Memorial Sloan-Kettering Cancer Center | Manufacturing processes for adoptive cell therapies |
CN117801108B (zh) * | 2023-12-06 | 2024-06-07 | 无锡傲锐东源生物科技有限公司 | 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1513934T1 (sl) * | 2002-06-06 | 2011-06-30 | Oncotherapy Science Inc | Geni in polipeptidi, povezani s humanimi raki kolona |
MX2008015132A (es) * | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
CN104080471B (zh) * | 2011-10-14 | 2018-08-10 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
RU2636000C2 (ru) * | 2012-02-28 | 2017-11-17 | Новартис Аг | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 |
-
2015
- 2015-04-21 EP EP15783044.9A patent/EP3134121A4/en not_active Withdrawn
- 2015-04-21 JP JP2016563850A patent/JP2017518040A/ja active Pending
- 2015-04-21 CR CR20160486A patent/CR20160486A/es unknown
- 2015-04-21 AU AU2015249887A patent/AU2015249887A1/en not_active Abandoned
- 2015-04-21 SG SG11201608715WA patent/SG11201608715WA/en unknown
- 2015-04-21 CN CN201580033599.1A patent/CN106714831A/zh active Pending
- 2015-04-21 WO PCT/US2015/026904 patent/WO2015164392A2/en active Application Filing
- 2015-04-21 MA MA039896A patent/MA39896A/fr unknown
- 2015-04-21 MX MX2016013857A patent/MX2016013857A/es unknown
- 2015-04-21 KR KR1020167032459A patent/KR20170010764A/ko unknown
- 2015-04-21 CA CA2946308A patent/CA2946308A1/en not_active Abandoned
- 2015-04-21 US US15/305,861 patent/US20170073430A1/en not_active Abandoned
- 2015-04-21 BR BR112016024525A patent/BR112016024525A2/pt not_active IP Right Cessation
- 2015-04-21 EA EA201692100A patent/EA201692100A8/ru unknown
-
2016
- 2016-10-17 PH PH12016502061A patent/PH12016502061A1/en unknown
- 2016-10-19 DO DO2016000283A patent/DOP2016000283A/es unknown
- 2016-10-19 IL IL248399A patent/IL248399A0/en unknown
- 2016-10-20 CL CL2016002667A patent/CL2016002667A1/es unknown
-
2017
- 2017-12-15 CL CL2017003240A patent/CL2017003240A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3134121A2 (en) | 2017-03-01 |
SG11201608715WA (en) | 2016-11-29 |
WO2015164392A8 (en) | 2016-12-29 |
EP3134121A4 (en) | 2017-11-08 |
PH12016502061A1 (en) | 2016-12-19 |
BR112016024525A2 (pt) | 2017-10-10 |
CL2016002667A1 (es) | 2017-07-07 |
CN106714831A (zh) | 2017-05-24 |
KR20170010764A (ko) | 2017-02-01 |
IL248399A0 (en) | 2016-11-30 |
CA2946308A1 (en) | 2015-10-29 |
WO2015164392A2 (en) | 2015-10-29 |
EA201692100A1 (ru) | 2017-02-28 |
EA201692100A8 (ru) | 2018-11-30 |
CL2017003240A1 (es) | 2018-06-01 |
US20170073430A1 (en) | 2017-03-16 |
CR20160486A (es) | 2017-02-20 |
MX2016013857A (es) | 2017-07-14 |
MA39896A (fr) | 2017-03-01 |
AU2015249887A1 (en) | 2016-11-03 |
JP2017518040A (ja) | 2017-07-06 |
WO2015164392A3 (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000283A (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
CY1122653T1 (el) | Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
UY37278A (es) | Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
CO2018005433A2 (es) | Conjugados de fármaco de anticuerpo her2 específicos de sitio | |
CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
ECSP17034845A (es) | Conjugados de anticuerpo- farmaco | |
DOP2018000138A (es) | Nuevos anticuerpos anti-claudina y sus métodos de uso | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
BR112015032224A2 (pt) | anticorpos anti-fcrh5 | |
CR20150048A (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
BR112015032718A2 (pt) | composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos | |
BR112018075644A2 (pt) | anticorpos anti-cd98 e conjugados de anticorpo e fármaco | |
CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso | |
BR112016029935A2 (pt) | ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo? | |
CO7151539A2 (es) | Anticuerpos e inmunoconjugados anti-cd22 |